Literature DB >> 9125220

Human immunodeficiency virus type 1 Vpr gene product prevents cell proliferation on mouse NIH3T3 cells without the G2 arrest of the cell cycle.

Y Nishino1, T Myojin, M Kamata, Y Aida.   

Abstract

Human immunodeficiency virus type 1 Vpr is a 96-amino-acid virion-associated protein that arrests cells in the G2 phase of the cell cycle in peripheral blood lymphocytes, HeLa, 293, 293T, A549, Jurkat, CEM, SupT1, CV-1 and COS1 cells. When we transfected Vpr expression vector into mouse NIH3T3 and then cultured it in the presence of G418, NIH3T3 cells were the drug resistant cells yielded. The surviving colonies, however, exhibited a degenerating morphology up to 8 approximately 20-fold smaller than the control vector colonies. In addition, the growth of NIH3T3 cells transiently transfected with Vpr expression vector declined dramatically compared with that of transfectants with control vector, suggesting that Vpr significantly interferes with cell proliferation of NIH3T3 cells. Cell cycle characterization by flow cytometry indicated that expression of Vpr did not induce G2 cessation in NIH3T3. These findings strongly suggest that Vpr has a novel pathway to retard cell growth independently and arrests the G2 phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9125220     DOI: 10.1006/bbrc.1997.6186

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Importin-alpha promotes passage through the nuclear pore complex of human immunodeficiency virus type 1 Vpr.

Authors:  Masakazu Kamata; Yuko Nitahara-Kasahara; Yoichi Miyamoto; Yoshihiro Yoneda; Yoko Aida
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Genetic studies with the fission yeast Schizosaccharomyces pombe suggest involvement of wee1, ppa2, and rad24 in induction of cell cycle arrest by human immunodeficiency virus type 1 Vpr.

Authors:  M Masuda; Y Nagai; N Oshima; K Tanaka; H Murakami; H Igarashi; H Okayama
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  HIV-1 Vif's Capacity To Manipulate the Cell Cycle Is Species Specific.

Authors:  Edward L Evans; Jordan T Becker; Stephanie L Fricke; Kishan Patel; Nathan M Sherer
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

4.  A carboxy-terminally truncated form of the human immunodeficiency virus type 1 Vpr protein induces apoptosis via G(1) cell cycle arrest.

Authors:  M Nishizawa; M Kamata; R Katsumata; Y Aida
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Two putative alpha-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two mechanisms.

Authors:  M Kamata; Y Aida
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2.

Authors:  Masakazu Kamata; Nobumoto Watanabe; Yoshiko Nagaoka; Irvin S Y Chen
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

7.  Vpr cytopathicity independent of G2/M cell cycle arrest in human immunodeficiency virus type 1-infected CD4+ T cells.

Authors:  Diane L Bolton; Michael J Lenardo
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

8.  Nuclear exportin receptor CAS regulates the NPI-1-mediated nuclear import of HIV-1 Vpr.

Authors:  Eri Takeda; Tomoyuki Murakami; Go Matsuda; Hironobu Murakami; Tamotsu Zako; Mizuo Maeda; Yoko Aida
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

9.  The human immunodeficiency virus type 1 Vpr protein and its carboxy-terminally truncated form induce apoptosis in tumor cells.

Authors:  Mizuho Nonaka; Yoshie Hashimoto; Shin-Nosuke Takeshima; Yoko Aida
Journal:  Cancer Cell Int       Date:  2009-08-12       Impact factor: 5.722

10.  Visualizing Vpr-induced G2 arrest and apoptosis.

Authors:  Tomoyuki Murakami; Yoko Aida
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.